Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma Front Oncol
A complex interplay between H2A.Z and HP1 isoforms regulates pericentric heterochromatin Front Cell Dev Biol
B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature LEUKEMIA LYMPHOMA
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors Front Immunol
Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas Clin Epigenetics
Long non-coding RNAs emerge as a novel prognostic indicator in pediatric acute myeloid leukemia Transl Pediatr
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center LEUKEMIA LYMPHOMA
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial Lancet Haematol